Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

Cancer Medicine

Volumn 2, Issue 6, 2013, Pages 925-932

  Forero Torres, Andres ^a   Infante, Jeffrey R ^b   Waterhouse, David ^c   Wong, Lucas ^d   Vickers, Selwyn ^e   Arrowsmith, Edward ^f   He, Aiwu Ruth ^g   Hart, Lowell ^h   Trent, David ⁱ   Wade, James ^j   Jin, Xiaoping ^k   Wang, Qiang ^k   Austin, Tashara ^k   Rosen, Michael ^k   Beckman, Robert ^k   von Roemeling, Reinhard ^k   Greenberg, Jonathan ^k   Saleh, Mansoor ^l  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Oncology Hematology Care   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Chattanooga Oncology and Hematology Associates PC   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h Florida Cancer Specialists   (United States)

ⁱ Virginia Cancer Institute   (United States)

^j Decatur Memorial Hospital   (United States)

^k DAIICHI SANKYO INC   (United States)

^l Georgia Cancer Specialists   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; PANCREATIC CANCER; PHASE 2; TIGATUZUMAB; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84903549192     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.137     Document Type: Article

References (30)